Get started
Author

Ivan Špička

Observed name: Ivan Špicka
Institution: Charles University
Observed institution: Charles University
OpenAlex ID: A5148728624
Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma
2026 · Gurdeep Parmar, Marcelo Capra, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-134: Durable Clinical Benefit of B-Cell Maturation Antigen–Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: DREAMM-8 Long-Term Responder Analysis
2026 · Meletios A Dimopoulos, Meral Beksaç, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-780: Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2026 · Marcelo Capra, Gurdeep Parmar, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1135: Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment Treated With at Least Two Prior Lines of Therapy in the DREAMM-7 Trial
2026 · Robert Rifkin, Habte Yimer, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-780: Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2026 · Marcelo Capra, Gurdeep Parmar, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-754: Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials
2026 · Xavier Leleu, Claudio Cerchione, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1135: Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment Treated With at Least Two Prior Lines of Therapy in the DREAMM-7 Trial
2026 · Robert Rifkin, Habte Yimer, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-754: Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials
2026 · Xavier Leleu, Claudio Cerchione, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-134: Durable Clinical Benefit of B-Cell Maturation Antigen–Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: DREAMM‐8 Long‐Term Responder Analysis
2026 · Meletios A Dimopoulos, Meral Beksaç, et al. · Clinical Lymphoma Myeloma & Leukemia
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone
2026 · Kwee Yong, Thomas Martin, et al. · Future Oncology
PDF
Autologous stem cell transplantation for newly diagnosed multiple myeloma - real-world data from 2,149 Czech patients
2026 · Tereza Popková, Luděk Pour, et al. · Haematologica
PDF
Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.
2026 · Xavier P. Leleu, Claudio Cerchione, et al. · Journal of Clinical Oncology
Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
2026 · Marcelo Capra, Gurdeep Parmar, et al. · Journal of Clinical Oncology
Isatuximab plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: Subgroup analysis by prior anti-CD38 exposure from the phase 3 IRAKLIA trial.
2026 · Albert Oriol Rocafiguera, Marek Hus, et al. · Journal of Clinical Oncology
PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2026 · Güldane Cengiz Seval, Sosana Delimpasi, et al. · Journal of Clinical Oncology
Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.
2026 · Suzanne Trudel, Güldane Cengiz Seval, et al. · Journal of Clinical Oncology
Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.
2026 · Meletios A. Dimopoulos, Meral Beksaç, et al. · Journal of Clinical Oncology
Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma
2026 · Jakub Halámek, Ivan Špička, et al. · Frontiers in Surgery
Works count: 18
Citation count:
H-index:
I10-index:
Year
Topic
Type